A. JAK2, CALR, and MPL B. ASXL1, SRSF2, and U2AF1Q157 C. JAK2, ASXL1, and MPL D. JAK2, CALR, and SRSF2 E. Unsure

A. The DIPSS stratifies patients into 4 risk groups: low risk, intermediate risk 1, intermediate risk 2, and high risk B. The DIPSS can be used as a prognostic tool at any point in the patient's disease course C. The DIPSS was developed in order to incorporate genetic data into prognostic information D. A patient's hemoglobin level is assigned more weight in the DIPSS than in the International Prognostic Scoring System (IPSS) E. Unsure

A. Patients with low-risk disease and a serum erythropoietin (EPO) level < 500 mU/mL without transfusion dependence B. Patients with low-risk disease and a serum EPO level < 500 mU/mL with a hemoglobin level < 8.5 g/dL at the start of treatment C. Patients who are refractory to danazol therapy D. Patients with intermediate risk 2 disease and a serum EPO level > 500 mU/mL with transfusion dependence E. Unsure

A. Allogeneic hematopoietic transplantation with myeloablative therapy B. Lenalidomide with prednisone C. Ruxolitinib D. Fedratinib E. Unsure

A. 20 twice daily B. 15 mg twice daily C. 10 mg twice daily D. 5 mg twice daily E. Unsure

A. Hold ruxolitinib and monitor complete blood count (CBC) in 2 weeks B. Decrease ruxolitinib by 5 mg twice daily and monitor CBC in 2 weeks C. Continue the current dosing and continue to monitor CBC every 2 weeks D. Discontinue ruxolitinib and change to another JAK inhibitor E. Unsure

A. Continue ruxolitinib at a higher dose B. Discontinue ruxolitinib and monitor splenomegaly symptoms C. Add lenalidomide to ruxolitinib therapy for a synergistic response D. Change JAK inhibitor therapy to fedratinib E. Unsure

A. Take fedratinib with a meal to prevent nausea B. Fedratinib has a black box warning regarding lipid elevations and frequent lipid panel checkups are required C. Fedratinib is a substrate of cytochrome P450 (CYP) 2D6 and, therefore, it is important for KG to inform his oncologist of any new medications D. To prevent the risk of Wernicke's encephalopathy, prophylactic thiamine must be given every week while on fedratinib therapy E. Unsure

A. Sotatercept is a first-in-class agent that causes red blood cell maturation by increasing circulating transforming growth factor (TGF) beta ligands B. Pacritinib is being studied in MF patients with platelet counts < 50 x 10⁹/L C. Momelotinib has shown statistical significance in superiority over best available therapy for reducing spleen size and decreasing symptom score in the SIMPLFY trials D. JAK inhibitors are not fit to be studied in combination with other agents due to increased toxicities E. Unsure

A. Evidence from a head-to-head trial of ruxolitinib versus fedratinib favors a formulary addition of ruxolitinib if one JAK inhibitor must be selected for an institution's treatment pathway B. Specialty pharmacies may need to obtain prior authorizations for JAK inhibitor third-party payer approvals C. Co-pay assistance programs are available for both ruxolitinib and fedratinib D. Though ruxolitinib is given twice daily and fedratinib is given daily, there is currently no evidence that one agent is better adhered to than the other E. Unsure